Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 189Neoplasm Metastasis 19Neoplasms 9Ovarian Neoplasms 8Breast Diseases 6Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Endometrial Neoplasms 4Advanced Breast Cancer 4Neoplasms by Site 3Lung Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Rectal Neoplasms 2Neoplasm, Residual 2Multiple Myeloma 2Melanoma 2Inflammation 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Estrogen Receptor-positive Breast Cancer 2

Interventions

pembrolizumab 24Nivolumab 7Early Intervention, Educational 7Methods 6durvalumab 5aldesleukin 5Trastuzumab 5Paclitaxel 5Fulvestrant 5Carboplatin 5atezolizumab 4Surveys and Questionnaires 4Patient Navigation 4Docetaxel 4Cyclophosphamide 4Biopsy 4fludarabine 3Mass Screening 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Interleukin-2 3Gene Expression Profiling 3Fluorouracil 3Educational Status 3Bevacizumab 3tremelimumab 2spartalizumab 2sargramostim 2palbociclib 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × palbociclib × Breast × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡